Equity (Tables)

6 Months Ended

Mar. 31, 2023

Equity [Abstract]

Schedule of Stock-based Compensation Expense - By Award Type

The following table sets forth stock-based compensation expense by award type:

	Three Months Ended March 31,				Six Months Ended March 31,
(in thousands)	2023		2022		2023		2022
Employee stock options	$	—	$	—	$	—	$	—
RSUs and RSAs	841		549		1,756		1,103
PSUs and PRSAs	608		487		1,301		894
Outside director equity awards and fees in common stock	86		108		212		235
Total stock-based compensation expense	$	1,535	$	1,144	$	3,269	$	2,232

Schedule of Stock-based Compensation Expense - By Expense Type

The following table sets forth stock-based compensation expense by expense type:

	Three Months Ended March 31,				Six Months Ended March 31,
(in thousands)	2023		2022		2023		2022
Cost of revenue	$	331	$	178	$	718	$	329
Selling, general, and administrative	951		781		2,026		1,536
Research and development	253		185		525		367
Total stock-based compensation expense	$	1,535	$	1,144	$	3,269	$	2,232

Schedule of (Loss) Income Per Share

The following table sets forth the computation of basic and diluted net (loss) income per share:

	Three Months Ended March 31,				Six Months Ended March 31,
(in thousands, except per share data)	2023		2022		2023		2022
Numerator
Net (loss) income	$	(12,228)	$	(2,225)	$	(23,921)	$	189
Denominator
Weighted average number of shares outstanding - basic	45,240		37,217		41,356		37,082
Effect of dilutive securities
Stock options	—		—		—		4
PSUs, RSUs, and restricted stock	—		—		—		1,298
Weighted average number of shares outstanding - diluted	45,240		37,217		41,356		38,384
Earnings per share - basic	$	(0.27)	$	(0.06)	$	(0.58)	$	0.01
Earnings per share - diluted	$	(0.27)	$	(0.06)	$	(0.58)	$	0.01
Weighted average antidilutive options, unvested RSUs and RSAs, and unvested PSUs excluded from the computation	2,947		75		2,732		72

Schedule of Common Stock Reserved for Future Issuances

Common stock reserved for future issuances as of March 31, 2023 was as follows:

	Amount
Exercise of outstanding stock options	9,981
Unvested RSUs and RSAs	4,100,023
Unvested PSUs and PRSAs (at 200% maximum payout)	2,865,486
Issuance of stock-based awards under the Equity Plans	1,894,567
Purchases under the officer and director share purchase plan	88,741
Total reserved	8,958,798